Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort
Mozaffari et al.
, Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause..
, Clinical Infectious Diseases, doi:10.1093/cid/ciab875
Retrospective 28,855 remdesivir patients with PSM matched controls, showing lower mortality with treatment.[Gérard, Wu, Zhou]
show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 12.0% lower, HR 0.88, p = 0.003, treatment 4,441 of 28,855 (15.4%), control 5,499 of 28,855 (19.1%), NNT 27, adjusted per study, 28 days, PSM, Cox proportional hazards.
risk of death, 24.0% lower, HR 0.76, p < 0.001, treatment 3,057 of 28,855 (10.6%), control 4,437 of 28,855 (15.4%), NNT 21, adjusted per study, 14 days, PSM, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mozaffari et al., 1 Oct 2021, retrospective, USA, peer-reviewed, 12 authors.
Abstract: Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of inhospital all-cause mortality in a large multi-center observational cohort
Essy Mozaffari1, Aastha Chandak2, Zhiji Zhang2, Shuting Liang1, Mark Thrun1, Robert L Gottlieb3,
Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA 94404; 2 Certara, 295 Madison Ave, 23rd Fl,
New York, NY, USA 10017; 3Baylor University Medical Center Dallas; Baylor Scott and White Heart
and Vascular Hospital; Baylor Scott and White The Heart Hospital Plano, and Baylor Scott and White
Research Institute, 3410 Worth St, Suite 250, Dallas TX, USA 75246; 4Division of Infectious Diseases,
Brigham and Women’s Hospital, Harvard Medical School, 65 Landsdowne St, Cambridge, MA, USA
02139; 5Division of Infectious Diseases, Brigham and Women’s Hospital, 75 Francis Street, Boston,
MA, USA 02115; 6University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC, USA 27599
Corresponding author details:
Robert L Gottlieb, MD, PhD
Advanced Heart Failure and Transplant Cardiologist
Baylor University Medical Center & Baylor Scott and White Research Institute
3410 Worth St, Suite 250, Dallas, TX, 75246 United States
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of
This is an Open Access article distributed under the terms of the Creative Commons AttributionNonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which
permits non-commercial reproduction and distribution of the work, in any medium, provided the
original work is not altered or transformed in any way, and that the work is properly cited. For
commercial re-use, please contact email@example.com
Daniel R. Kuritzkes4, Paul E. Sax5, David A. Wohl6, Roman Casciano2, Paul Hodgkins1, Richard
Summary: Patients treated with remdesivir had a significantly lower risk of mortality compared to
those not treated with remdesivir. Consistent with other studies, this large study of U.S. clinical
practice supports remdesivir as a treatment option for appropriate COVID-19 patients.
Background: Remdesivir (RDV) improved clinical outcomes among hospitalized COVID-19 patients in
randomized trials, but data from clinical practice are limited.
Nov 2020 and treated with RDV within two-days of hospitalization vs. those not receiving RDV during
their hospitalization using the Premier Healthcare Database. Preferential within-hospital propensity
score matching with replacement was used. Additionally, patients were also matched on baseline
oxygenation level (no supplemental oxygen charges (NSO), low-flow oxygen (LFO), high-flow
oxygen/non-invasive ventilation (HFO/NIV) and invasive mechanical ventilation/ECMO (IMV/ECMO)
and two-month admission window and excluded if discharged within 3-days of admission (to exclude
anticipated discharges/transfers within 72-hrs consistent with ACTT-1 study). Cox Proportional
Hazards models were used to assess time to 14-/28-day mortality overall and for patients on NSO,
LFO, HFO/NIV and IMV/ECMO.
Results: 28,855 RDV patients were matched to 16,687 unique non-RDV patients. Overall, 10.6% and
15.4% RDV patients..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.